Andrew R. Zolopa

Andrew R. Zolopa publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Andrew R. Zolopa sits on this spectrum.

Andrew R. Zolopa D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew R. Zolopa sits on this spectrum.

Best Publications

• Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

  David R. Bangsberg;Frederick M. Hecht;Edwin D. Charlebois;Andrew R. Zolopa

  1350
  Citations

• Non-adherence to highly active antiretroviral therapy predicts progression to Aids

  David R. Bangsberg;Sharon Perry;Edwin D. Charlebois;Richard A. Clark

  1227
  Citations

• Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

  Andrew R. Zolopa;Janet Andersen;Lauren Komarow;Ian Sanne

  712
  Citations

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

  Paul E. Sax;Edwin DeJesus;Anthony Mills;Andrew Zolopa

  593
  Citations

• The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan

  Victor DeGruttola;Lynn Dix;Richard D'Aquila;Dan Holder

  449
  Citations

• High levels of adherence do not prevent accumulation of HIV drug resistance mutations.

  David R Bangsberg;Edwin D Charlebois;Robert M Grant;Mark Holodniy

  356
  Citations

• Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.

  Phyllis C Tien;Andy I Choi;Andrew R Zolopa;Constance Benson

  349
  Citations

• Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

  Roy M. Gulick;Zhaohui Su;Charles Flexner;Michael D. Hughes

  316
  Citations

• Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

  Thomas D. Wu;Celia A. Schiffer;Matthew J. Gonzales;Jonathan Taylor

  296
  Citations

• HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample.

  Andrew R. Zolopa;Judith A. Hahn;Robert Gorter;Jeanne Miranda

  284
  Citations

• HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.

  Andrew R. Zolopa;Robert W. Shafer;Ann Warford;Jose G. Montoya

  274
  Citations

• Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: A randomized phase 2 study

  Paul E. Sax;Andrew Zolopa;Indira Brar;Richard Elion

  270
  Citations

• HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance

  Soo-Yon Rhee;Jonathan Taylor;W. Jeffrey Fessel;David Kaufman

  267
  Citations

• A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.

  Andrew Zolopa;Paul E. Sax;Edwin Dejesus;Anthony Mills

  205
  Citations

• Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection

  Philip M. Grant;Lauren Komarow;Janet Andersen;Irini Sereti

  195
  Citations

• Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug-Resistant HIV-1 Infection

  Thomas B. Campbell;Nancy S. Shulman;Steven C. Johnson;Andrew R. Zolopa

  169
  Citations

• Evidence for Genetic Regulation of Susceptibility to Toxoplasmic Encephalitis in AIDS Patients

  Yasuhiro Suzuki;Sin-Yew Wong;F. Carl Grumet;Jeffrey Fessel

  165
  Citations

• Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults

  Martin Markowitz;Andrew Zolopa;Kathleen Squires;Peter Ruane

  162
  Citations

• HIV-1 Protease and Reverse-Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance

  Soo-Yon Rhee;W. Jeffrey Fessel;Andrew R. Zolopa;Leo Hurley

  155
  Citations

• Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors

  Matthew J. Gonzales;Thomas D. Wu;Jonathan Taylor;Ilana Belitskaya

  151
  Citations